Bayer has acquired the German biotech company, Direvo, in an all cash deal to bolster its biologicals pipeline. Through its protein engineering platform, Direvo was developing therapeutic antibodies and proteases to treat a range of diseases such as rheumatoid arthritis and Crohn’s disease and blood disorders.